Recommendations for therapeutic monitoring of antidepressants;Dosage plasmatique des médicaments antidépresseurs

Revue Medicale Suisse

Volumn 9, Issue 377, 2013, Pages 577-586

  Baumann, Pierre ^a   Rougemont, Michael ^a   Corruble, Emmanuelle ^b   Hiemke, Christoph ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Universite Paris Sud   (France)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; PATIENT COMPLIANCE; PHARMACOGENETICS; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; DRUG INTERACTION; METHODOLOGY;

ANTIDEPRESSIVE AGENTS; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; MEDICATION ADHERENCE; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC;

MLCS; MLOWN;

EID: 84875321201     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bazire S. Psychotropic drug directory. The professional's pocket handbook and aide memoire. Aberdeen : Health Comm UK Ltd, 2011.
2. Baumann P, Hiemke C, Ulrich S, et al. The AGNPTDM expert group consensus guidelines : Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37:243-65.
3. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry : Update 2011. Pharmacopsychiatry 2011;44:195-235.
4. Baumann P, Hiemke C, Ulrich S, et al. Le dosage plasmatique des médicaments psychotropes à des fins thérapeutiques : recommandations du groupe d'experts AGNP-TDM. Rev Med Suisse 2006;2:1413-26.
5. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31:493-502.
6. Reis M, Aberg-Wistedt A, Agren H, Akerblad AC, Bengtsson F. Compliance with SSRI medication during 6 months of treatment for major depression : An evaluation by determination of repeated serum drug concentrations. J Affect Disord 2004;82:443-6.
7. Baumann P, Zullino DF, Eap CB. Enantiomers' potential in psychopharmacology - a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002;12:433-44.
8. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:289-95.
9. Court MH. Interindividual variability in hepatic drug glucuronidation : Studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 2010;42:209-24.
10. Mrazek DA. Psychiatric pharmacogenomics. Oxford : Oxford University Press, 2010.
11. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics : The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-73.
12. Valdes RJ, Payne DA, Linder MW. Laboratory medicine practice guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. Washington DC : National Academy of Clinical Biochemistry, 2010.
13. Tanaka E, Kurata N, Yasuhara H. How useful is the cocktail approach for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo ? J Clin Pharm Ther 2003;28:157- 65.
14. de Lange EC. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 2004;56:1793-809.
15. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57:203-9.
16. Grunder G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I. Therapeutic plasma concentrations ofantidepressants and antipsychotics : Lessons from PET imaging. Pharmacopsychiatry 2011;44:236-48.
17. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. Review (191 refs). J Psychiatry Neurosci 2007; 32:86-102.
18. Haen E, Greiner C, Bader W, Wittmann M. Expanding therapeutic reference ranges using dose-related reference ranges. Nervenarzt 2008;79:558-66.
19. Ulrich S, Läuter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet 2002;41:853-76.
20. Asberg M, Cronholm B, Sjöqvist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 1971;3:331-4.
21. Dawling S. Monitoring of tricyclic antidepressant therapy. Clin Biochem 1982;15:56-61.
22. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma : An estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994;14:230-40.
23. Gilles M, Deuschle M, Kellner S, et al. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 2005;38:118-21.
24. Waldschmitt C, Vogel F, Pfuhlmann B, Hiemke C. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. Pharmacopsychiatry 2009;42:189-93.
25. Gaertner I, Gaertner HJ, Vonthein R, Dietz K. Therapeutic drug monitoring of clozapine in relapse prevention : A five-year prospective study. J Clin Psychopharmacol 2001;21:305-10.
26. Reis M, Akerblad AC, Ekselius L, von Knorring L. Partial compliance as determined from plasma levels of sertraline and its metabolite in depressed patients in primary care. J Clin Psychopharmacol 2010;30:746-8.
27. Fric M, Pfuhlmann B, Laux G, et al. The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry 2008;41:151-5.
28. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Ann Rev Med 2006;57:119-37.
29. Jaquenoud Sirot E, Van der Velden JW, Rentsch K, Eap CB, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006;29:735-68.
30. Kootstra-Ros JE, van Weelden MJ, Hinrichs JW, et al. Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. J Clin Pharmacol 2006;46:1320-7.
31. Steimer W. Pharmacogenetics and psychoactive drug therapy : Ready for the patient ? Ther Drug Monit 2010;32:381-6.